Sunstone makes €5 million investment into Finnish women’s health company Forendo Pharma to finance clinical studies in endometriosis

by | Jul 17, 2019

Sunstone Life Science Ventures today announced its first investment out of its Life Science Ventures Fund IV into Forendo Pharma, a Finnish clinical stage drug development company focusing on novel treatments in women’s health.

The investment is designated to finance the continuation of Forendo Pharma’s positive Phase Ia study in post-menopausal women into Phase Ib in pre-menopausal women, and later Phase II for the treatment of endometriosis.

Press inquiries should be adressed to:

Claus Andersson, PhD

General Partner